Market Tracker

07/01 5:16pm ET

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

61.44
Delayed Data
As of Jul 01
 +5.95 / +10.72%
Today’s Change
49.96
Today|||52-Week Range
137.89
-34.74%
Year-to-Date
Why Alnylam Pharmaceuticals, Inc. Jumped 10.7% on Friday
Jul 01 / MotleyFool.com - Paid Partner Content
3 Biotech Stocks to Buy in July
Jun 25 / MotleyFool.com - Paid Partner Content
Barbarian At The Gate: Alnylam Pharmaceuticals (ALNY)
Jul 01 / TheStreet.com - Paid Partner Content
'Mad Money' Lightning Round: Buy, Buy, Buy UnitedHealth Group
Jun 25 / TheStreet.com - Paid Partner Content
Alnylam Pharmaceuticals (ALNY) Highlighted As Today's Perilous Reversal Stock
Jun 29 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close55.49
Today’s open55.00
Day’s range53.56 - 61.64
Volume1,453,262
Average volume (3 months)998,952
Market cap$4.7B
Dividend yield--
Data as of 4:00pm ET, 07/01/2016

Growth & Valuation

Earnings growth (last year)+28.87%
Earnings growth (this year)-43.49%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)-18.72%
P/E ratioNM
Price/Sales192.40
Price/Book3.73

Competitors

 Today’s
change
Today’s
% change
CRLCharles River Labora...+0.86+1.04%
ICLRICON PLC+0.63+0.90%
PRXLPAREXEL Internationa...+0.59+0.94%
IONSIonis Pharmaceutical...+1.13+4.85%
Data as of 4:02pm ET, 07/01/2016

Financials

Next reporting dateAugust 4, 2016
EPS forecast (this quarter)-$1.25
Annual revenue (last year)$41.1M
Annual profit (last year)-$290.1M
Net profit margin-705.83%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President &
Chief Operating Officer
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts